Clinical Trial

The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the clinical efficacy of everolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-24; most recent amendment 2026-04-05.
Trial Details
NCT Number NCT07095933
Lead Sponsor Xuanwu Hospital, Beijing
Conditions Epilepsy, Drug Resistant
Enrollment 5 participants
Start Date 2026-07-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-07